IART - צמיחת הכנסות ב-12 חודשים נגררים Integra LifeSciences Inc.

Large-scale product recalls due to quality defects are weighing on quotes, and after analyzing the chart on GURU.Markets, we find that the year-over-year sales trajectory (TTM) has stalled at 0.90. A network of high-tech plants in Europe and the US ensures supply stability for Integra LifeSciences (IART). Specialized sterile transport methods to operating rooms guarantee the reliable delivery of fragile neurosurgical instruments.

Silicon supply chain disruptions and export restrictions on neurosurgical equipment directly impact the revenue of Integra LifeSciences (IART). This metric measures the percentage change in sales volume over a trailing twelve-month period, neutralizing quarterly seasonality and reflecting the business's actual expansion rate. By analyzing the year-over-year (TTM) operating revenue trend, an investor determines the company's resilience to geopolitical shocks and the accuracy of the market consensus.